Dafinchi AI

Integer Holdings Corporation

ITGR

Healthcare

3w

Financial Performance Summary

Adjusted earnings per share increased 19% year-over-year to $1.55.
Adjusted net income for Q2 was $55 million, up 23% year-over-year, driven by operational improvements and lower interest expense.
Adjusted operating income grew 15% year-over-year, with margin expansion of 50 basis points to 17.1%.
For the first half of 2025, sales increased 9% and adjusted operating profit increased 14%, outperforming sales growth by 1.5x.
Free cash flow in Q2 was $25 million, a 55% improvement from prior year, with $44 million cash flow from operations and $19 million CapEx.
In Q2 2025, Integer reported sales of $476 million, an 11% year-over-year increase on both reported and organic basis.
Net total debt decreased by $25 million from Q1 to $1.204 billion, with leverage at 3.2x trailing 4 quarter adjusted EBITDA.

Revolution Medicines, Inc.

RVMD

Healthcare

1w

Financial Performance Summary

G&A expenses rose to $40.6 million in Q2 2025 from $21.7 million in Q2 2024 due to increased personnel and commercial preparation activities.
Net loss for Q2 2025 was $247.8 million, up from $133.2 million in Q2 2024, mainly due to higher operating expenses.
R&D expenses increased to $224.1 million in Q2 2025 from $134.9 million in Q2 2024, driven by clinical trial and manufacturing costs, primarily for daraxonrasib.
Revolution Medicines ended Q2 2025 with $2.1 billion in cash and investments, including a $250 million royalty monetization tranche from Royalty Pharma.
The Royalty Pharma transaction was accounted for as a liability, with $900,000 noncash interest expense recognized in Q2 2025.
Updated 2025 GAAP net loss guidance is between $1.03 billion and $1.09 billion, reflecting increased expenses from global development and commercialization plans.

Masimo Corporation

MASI

Healthcare

1w

Financial Performance Summary

Gross margin improved by 40 basis points to 62.9%, despite a 50 basis point tariff impact.
Masimo's core Healthcare business reported Q2 2025 revenue of $370 million, up 7.4% on a constant currency basis.
Non-GAAP earnings per share (EPS) grew 46% year-over-year to $1.33, driven by operational improvements and a lower tax rate.
Operating cash flow was $62 million, enabling $38 million debt repayment and $14 million in share repurchases.
Operating margin expanded by 600 basis points year-over-year to 27.5%, reflecting cost structure optimizations and tariff mitigation.

Harmony Biosciences Holdings, Inc.

HRMY

Healthcare

2w

Financial Performance Summary

Cash generated from operations was approximately $79 million in the quarter, with a strong cash position of over $670 million.
Harmony Biosciences reported second quarter 2025 net revenues of $200.5 million, a 16% increase year-over-year from $172.8 million in Q2 2024.
The company extended its 4-year streak of profitability with non-GAAP adjusted net income of $53.8 million or $0.92 per diluted share, compared to $24.5 million or $0.43 per diluted share in the prior year quarter.
The financial results reflect strong underlying demand for WAKIX, offset by a slight reduction in trade inventories heading into summer months.
Total operating expenses for Q2 2025 were $114.2 million, down from $119.3 million in the same quarter last year.

Mersana Therapeutics, Inc.

MRSN

Healthcare

6d

Financial Performance Summary

Collaboration revenue increased to $3.1 million from $2.3 million year-over-year, driven by J&J and Merck KGaA agreements.
Ended Q2 2025 with $77 million in cash and cash equivalents.
General and administrative expenses declined to $7.4 million from $10.5 million, due to lower headcount and reduced consulting fees.
Incurred $3.9 million in restructuring charges related to severance and related expenses.
Net cash used in operating activities was $22.6 million, including $2.4 million in severance payments.
Net loss remained flat at $24.3 million compared to Q2 2024.
Paid off $17.9 million debt facility in July 2025.
R&D expenses decreased to $16.2 million from $17.2 million, reflecting lower headcount but increased clinical and manufacturing costs.